Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

Better renoprotective effect of angiotensin II antagonist compared to dihydropyridine calcium channel blocker in childhood.

Gartenmann AC, Fossali E, von Vigier RO, Simonetti GD, Schmidtko J, Edefonti A, Bianchetti MG.

Kidney Int. 2003 Oct;64(4):1450-4.

2.

Treatment of diabetic nephropathy with angiotensin II receptor antagonist.

Lewis EJ, Lewis JB.

Clin Exp Nephrol. 2003 Mar;7(1):1-8. Review.

PMID:
14586737
3.

Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy.

Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL, Drury PL, Esmatjes E, Hricik D, Parikh CR, Raz I, Vanhille P, Wiegmann TB, Wolfe BM, Locatelli F, Goldhaber SZ, Lewis EJ; Irbesartan Diabetic Nephropathy Trial. Collaborative Study Group.

Ann Intern Med. 2003 Apr 1;138(7):542-9.

PMID:
12667024
4.

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.

Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I; Collaborative Study Group.

N Engl J Med. 2001 Sep 20;345(12):851-60.

5.

Comparison of monotherapy with irbesartan 150 mg or amlodipine 5 mg for treatment of mild-to-moderate hypertension.

Neutel JM, Germino FW, Smith D.

J Renin Angiotensin Aldosterone Syst. 2005 Sep;6(2):84-9.

PMID:
16470487
6.

The Irbesartan type II diabetic nephropathy trial: study design and baseline patient characteristics. For the Collaborative Study Group.

Rodby RA, Rohde RD, Clarke WR, Hunsicker LG, Anzalone DA, Atkins RC, Ritz E, Lewis EJ.

Nephrol Dial Transplant. 2000 Apr;15(4):487-97.

8.

A clinical trial in type 2 diabetic nephropathy.

Lewis EJ, Hunsicker LG, Rodby RA; Collaborative Study Group.

Am J Kidney Dis. 2001 Oct;38(4 Suppl 1):S191-4.

PMID:
11576953
9.

Effectiveness and safety of the angiotensin II antagonist irbesartan in children with chronic kidney diseases.

Franscini LM, Von Vigier RO, Pfister R, Casaulta-Aebischer C, Fossali E, Bianchetti MG.

Am J Hypertens. 2002 Dec;15(12):1057-63.

PMID:
12460701
10.

Preliminary experience with the angiotensin II receptor antagonist irbesartan in chronic kidney disease.

von Vigier RO, Zberg PM, Teuffel O, Bianchetti MG.

Eur J Pediatr. 2000 Aug;159(8):590-3.

PMID:
10968237
11.

Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine.

Corea L, Cardoni O, Fogari R, Innocenti P, Porcellati C, Provvidenza M, Meilenbrock S, Sullivan J, Bodin F.

Clin Pharmacol Ther. 1996 Sep;60(3):341-6.

PMID:
8841157
13.

Renin inhibition by aliskiren prevents atherosclerosis progression: comparison with irbesartan, atenolol, and amlodipine.

Nussberger J, Aubert JF, Bouzourene K, Pellegrin M, Hayoz D, Mazzolai L.

Hypertension. 2008 May;51(5):1306-11. doi: 10.1161/HYPERTENSIONAHA.108.110932. Epub 2008 Apr 7.

14.

Comparative effects of candesartan cilexetil and amlodipine in patients with mild systemic hypertension. Comparison of Candesartan and Amlodipine for Safety, Tolerability and Efficacy (CASTLE) Study Investigators.

Kloner RA, Weinberger M, Pool JL, Chrysant SG, Prasad R, Harris SM, Zyczynski TM, Leidy NK, Michelson EL; Comparison of Candesartan and Amlodipine for Safety, Tolerability and Efficacy (CASTLE) Study Investigators.

Am J Cardiol. 2001 Mar 15;87(6):727-31.

PMID:
11249891
15.

L/N-type calcium channel blocker cilnidipine reduces plasma aldosterone, albuminuria, and urinary liver-type fatty acid binding protein in patients with chronic kidney disease.

Abe M, Maruyama N, Suzuki H, Inoshita A, Yoshida Y, Okada K, Soma M.

Heart Vessels. 2013 Jul;28(4):480-9. doi: 10.1007/s00380-012-0274-1. Epub 2012 Aug 23.

PMID:
22914905
16.

Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension.

White WB, Duprez D, St Hillaire R, Krause S, Roniker B, Kuse-Hamilton J, Weber MA.

Hypertension. 2003 May;41(5):1021-6. Epub 2003 Apr 7. Erratum in: Hypertension. 2003 Dec;42(6):e20.

17.

Interim evidence of the renoprotective effect of the angiotensin II receptor antagonist losartan versus the calcium channel blocker amlodipine in patients with chronic kidney disease and hypertension: a report of the Japanese Losartan Therapy Intended for Global Renal Protection in Hypertensive Patients (JLIGHT) Study.

Iino Y, Hayashi M, Kawamura T, Shiigai T, Tomino Y, Yamada K, Kitajima T, Ideura T, Koyama A, Sugisaki T, Suzuki H, Umemura S, Kawaguchi Y, Uchida S, Kuwahara M, Yamazaki T; Japanese Lasartan Therapy Intended for the Global Renal Protection in Hypertensive Patients (JLIGHT) Study Investigators.

Clin Exp Nephrol. 2003 Sep;7(3):221-30.

PMID:
14586719
18.

Irbesartan/amlodipine: a review of its use in adult patients with essential hypertension not adequately controlled with monotherapy.

Garnock-Jones KP.

Am J Cardiovasc Drugs. 2013 Apr;13(2):141-50. doi: 10.1007/s40256-013-0014-7. Review.

PMID:
23516133
Items per page

Supplemental Content

Write to the Help Desk